1998

• Steven A. Kilgore is granted Patent US5782779A for the VIPON, described as a “vibrating tampon apparatus for easing a woman’s menstrual cramps”.
• Patent assigned to Another Way Products, LLC.

1999

• Clinical Practice Report on the VIPON by Dr. Kermit E. Krantz, Chairman of Ob-Gyn Dept – University of Kansas School of Medicine (KU).
• All 8 subjects reported pain relief from Dysmenorrhea.

2000

• FDA grants 510(k) marketing clearance to the VIPON  (510(k) K992493
• Indication of Use: Absorption of menstrual fluid (tampon).  Clinical Trial required to support an Indication for relief from Dysmenorrhea.

2002  to  2005

• Clinical Trial Protocol Development for VIPON, Contract Negotiations with CRO (Alquest/NAMSA)  & Study Sites, Fund Raising.

2006

• Clinical Trial Begins:   “A Comparison Study of Pain Relief From Dysmenorrhea Between the Vipon Tampon and Ibuprofen”,  NCT00951561.

2009

• Clinical Trial Completed:  Data showed VIPON to be non-inferior to Ibuprofen for relief of Dysmenorrhea. Statistical analysis showed VIPON to be significantly faster acting than Ibuprofen.   See Clinical Trial Study Report for details.

2008  to  2011

• Opened negotiations with Ruggli, AG (a Swiss Company) to mass produce VIPON
• After testing VIPON and reviewing our clinial trial data, DAX Holdings, AG (a Swiss company and owner of Ruggli) proposes we form a joint venture.  
• Formed VIPON AG;   a joint venture formed between Another Way Products and DAX Holdings, AG (a Swiss company).
• VIPON was redesigned for mass production & renamed: TAMIA.  Tamia received marketing clearance from SWISSMEDIC for relief of Dysmenorrhea
• VIPON AG ceased operations when test marketing showed that TAMIA’s price was too high for a disposable / single-use product.

2012

• Medical Journal Publication:   Tamia Clinical Practice Report (Gynecology, April 2012)

2013

• Medical Journal Publication: Vipon Clinical Trial Report  (Journal of Women’s Health: June 2013).

2021

• Leveraging the knowledge gained from developing VIPON and Tamia, our earlier devices, David Conroy turned to the voices of women. Their insights guided the design of WAVE, prioritizing a reusable product that eliminated the need for a tampon and lowered the effective cost to the user.

2022

• Prototype WAVE was built that successfully met all design goals.  

2023

• Bench testing of the finished product showed that the performance characteristics of WAVE’s vibratory stimulus were comparable to that of VIPON. 
• Hush Tech LLC is formed to commercialize WAVE.
• Utililty Patent filed for “FlexStem” delivery system
• Design Patent filed for WAVE design

2024  

• WAVE becomes an FDA  Listed, OTC, Class 2, 510(k) exempt, Medical Device listed under FDA product code: KXQ
• Preparing to file FDA 510(k) to obtain marketing clearance for Wave with Indication of Use for the Relief of Dysmenorrhea.
• Launched retail website:     WaveByHush.com 
• ACOG  Medical  Conference  approves WAVE device to be Exhibited in “Innovation Lane” ;  Booth 746,  Minneapolis, MN  May 16 to 18